A. Necchi provides an expert overview across data from atezolizumab, durvalumab and nivolumab studies in urothelial cancer as presented at ASCO 2016 Annual Meeting. It is an exciting time in this field; after decades of therapeutic silence these agents provide 25-30% response rate in the overall population in relapsed setting and 8 month overall survival with observed increase in patients with PD-L1-positive tumours. The problem will be to identify patients who may benefit from the treatment.